NCT04887870 - Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 29, 2021

Primary Completion Date

April 21, 2025

Study Completion Date

September 25, 2025

Conditions

Advanced or Metastatic Solid Malignancies

Interventions

DRUG

Sitravatinib

Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.

DRUG

Nivolumab

Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

DRUG

Pembrolizumab

Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody

DRUG

Enfortumab Vedotin-Ejfv

Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)

DRUG

Ipilimumab

Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody

Trial Locations (13)

10065

Memorial Sloan Kettering Cancer Center - Arnold and Marie Schwartz Cancer Research Building, New York

12208

Local Institution - 516-014-011, Albany

22031

NEXT Virginia, Fairfax

43210

Local Institution - 516-014-004, Columbus

46526

Local Institution - 516-014-029, Goshen

48201

Barbara Ann Karmanos Cancer Institute, Detroit

55455

Local Institution - 516-014-005, Minneapolis

68130

Urology Cancer Center and GU Research Network, Omaha

75020

USOR - Texas Oncology Northeast Texas - Denison, Denison

77030

Local Institution - 516-014-013, Houston

78758

Local Institution - 516-014-001, Austin

80218

Rocky Mountain Cancer Centers - Littleton, Littleton

02215

Local Institution - 516-014-002, Boston